LONDON - Treating patients with advanced kidney cancer before surgery with a combination of targeted therapies is safe, effective and may prolong their lives, researchers said on Thursday.Scientists at the University of Texas MD Anderson Cancer Centre, who presented their findings at a conference in Prague, studied the effect of giving the drugs bevacizumab and erlotinib to patients before their tumour was removed.
“The main aim of this study was to look at the efficacy and safety of using these targeted therapies before surgery, and our results have shown that there were few side effects and that it prolonged the survival of our patients,” said Eric Jonasch, a professor of medicine at the university.
Continue reading Drug combo effective for kidney cancer.
